Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

Dentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.

Original reporting
Published Sep 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$XRAY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Med
01

Why it matters

The earnings beat provides limited catalyst; investors will watch guidance and cash flow trends.

02

Market read

Earnings release adds new data for a mid‑cap healthcare equipment stock, offering modest trading ideas.

03

What to watch

Tariff refunds and working‑capital improvements boosted operating cash flow, which may be undervalued by the market.

Relevance 7/10Novelty 7/10Timing: post‑market earnings release

Background

Dentsply Sirona has struggled with lower volumes and product mix pressure, leading to a prolonged downtrend.

Market effects

Dental equipment sector may see slight pressure as peers face similar volume challenges.

U.S. healthcare equipment stocks could see modest re‑rating.

Limited; impact confined to U.S. listed dental equipment companies.

Counterpoint

Despite the low price, the 6.3% dividend yield and cash flow improvement could attract income‑focused investors.

Key entities

  • Dentsply Sirona Inc.

    U.S. dental equipment manufacturer

Related articles

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.